If you have the cash to invest and are willing to let time be an ally, the following two stocks all have the potential to turn $100,000 into $1 million by year 2030.
Telehealth giant Teladoc Health was one of the biggest disappointments of 2021. After soaring during the beginning stages of the Covid pandemic, concerns about bigger-than-expected losses connected to its Livongo Health acquisition, drove shares over 70% below their all-time high.
However, traders with time on their side could buy Teladoc Health now and take pride in owning a top innovator in personalized care.
The best way to tell that telemedicine is here to stay is to take a look at Teladoc’s sales growth before the pandemic. In the seven years that led up to the outbreak of the coronavirus, the company had averaged yearly sales growth of 74%. That is not a year or two of just being in the right place at the right time. Sales growth that is this consistent signals a sustained shift in the way that treatment is being administered within the U.S.
The best thing about telemedicine is that it gives benefits up and down the treatment chain. It is almost always more convenient for its patients, and it allows physicians to have easier access to chronically ill patients. The easy access should result in better patient outcomes and decreased costs for health insurance businesses.
What’s more, the increased costs associated with Teladoc’s buyout of top applied health signals company Livongo Health will not carry over into its 2022 financial results. This means traders can focus on what is important — i.e., Livongo’s efforts to attract more chronic-care members to its service.
Teladoc has the innovation and solutions to be one of the quickest-growing healthcare stocks this decade.
A small-cap growth stock with big-cap aspirations that might realistically 10x investors’ cash by the turn of the decade is PubMatic.
PubMatic is a cloud-based, sell-side programmatic ad platform. In more simple terms, this means PubMatic’s solutions manage the optimization of ad placement for its customers, the publishers selling their display space. While publishers do provide some level of input, such as the minimum price they would be willing to accept for their display space, it is PubMatic’s programmatic ad platform that manages everything else.
What makes PubMatic such a great buy over the long term is the undeniable shift of advertising money to digital platforms. According to the business, global digital ad investments have been predicted to grow by a yearly rate of 10% through year 2024, with respective compound yearly growth rates of 11%, 17%, and 11% for video, mobile, and connected TV ads through 2025.
With this shift to investing in digital ads picking up steam, PubMatic is looking like the best name to own in the programmatic ad space.